BIIB

Biogen is a stabilizing-but-not-yet-growing story. FY2025 revenue of $9.89B ticked up +2.2%, the first increase after a multi-year slide from $11.0B (FY2021) → $9.68B (FY2024), suggesting the legacy MS erosion is finally being offset by newer launches. But the quality of that top line is deteriorating: net income fell -20.8% to $1.29B, diluted EPS dropped -21.4% to $8.79, and operating cash flow fell -23.3% to $2.20B. ROE is a thin 7.1%. So the print is 'revenue flat, profits shrinking' — the opposite of the consistent, profitable growth I reward.

The MD&A confirms the core problem is structural franchise erosion. Multiple TECFIDERA generics are now in North America, Brazil and Europe at deeply discounted prices, and in November 2025 the EPO's Technical Boards of Appeal revoked Biogen's EP 2 653 873 patent — Biogen has stopped enforcing it, so that decline accelerates from here. A TYSABRI biosimilar (approved 2023) is also eating a second legacy pillar. The bull case rests on newer assets — LEQEMBI in Alzheimer's (with Eisai), SKYCLARYS in Friedreich's ataxia, QALSODY in ALS, SPINRAZA in SMA, ZURZUVAE in PPD — plus the Genentech anti-CD20 economics. These are real but unproven at scale, and the filing's aggressive business development (Stoke $165M upfront, HI-Bio $300M milestones, Alcyone, Royalty Pharma R&D funding) shows management buying pipeline rather than harvesting organic growth.